The disclosure relates to the use of a family of compounds of general structure (II) where the unspecified groups are defined in the specification, for the treatment of hepatic steatosis. The compound or pharmaceutically acceptable salt thereof is a present in a composition that further comprises a pharmaceutically acceptable vehicle or carrier and may be formulated for oral administration such as in a tablet or capsule. The compounds used include: 6-[1-(3-Hydroxy-4-methoxy-benzyl)-piperidin-4-yl]-2-piperidin-1-yl-pyrimidin-4-ol